Edda Pjrek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Edda Pjrek has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
- Dietmar Winkler
Department of Psychiatry and Psychotherapy, Medical University of Vienna
47 shared publications - Siegfried Kasper
Medizinische Universität Wien
34 shared publications - Nicole Praschak-Rieder
Medical University Vienna
12 shared publications - Matthäus Willeit
Department of Psychiatry and Psychotherapy, Division of General Psychiatry, Medical University of Vienna, Vienna, Austria
11 shared publications Siegfried Kasper
Department of Psychiatry and Psychotherapy, Medical University of VIenna, Vienna, Austria
10 shared publicationsAnastasios Konstantinidis
Department of Psychiatry and Psychotherapy, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria
9 shared publications
Latest Publications
- Open Access
- 23 June 2026
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 69 (1) , 1-27
Real-world effectiveness and safety of intranasal esketamine for treatment-resistant depression: data from the enTRD registry
Background: Real-world data for intranasal esketamine in treatment-resistant depression (TRD) are needed to characterize effectiveness, suicidality, and tolerability in routine care. We evaluated induction phase outcomes in outpatients with TRD treated at the University Hospital Vienna. Methods: This retrospective single-center registry study included adults with TRD initiating supervised intranasal esketamine. The primary endpoint was the change in clinician-rated depressive symptom severity (MADRS) from the pre-treatment (PV) to the end of induction (EOI) visit. MADRS scores across baseline (BL), PV, and EOI were analyzed using a mixed model for repeated measures. Secondary outcomes included MADRS three-factor change, self-rated depression score trajectories (PHQ-9), response/remission rates, suicidal ideation, and tolerability. Results: Of 229 screened patients, 176 initiated esketamine and 156 completed induction. MADRS at BL was 31.5 (SD 6.4), PHQ-9 was 18.5 (SD 4.7). In the primary model, adjusted mean MADRS was 30.3 at PV and 17.7 at EOI, yielding a change of −12.5 points (95%CI −14.1 to −11.0; p < 0.001; Hedges’ g = 1.8). All MADRS factors improved, with the largest reduction in the affective–anhedonic domain. PHQ-9 decreased steadily across treatments. Remission was 27.2% and response 57.4% at EOI. Suicidal ideation decreased significantly; no suicide or serious self-harm occurred during induction. Adverse events (AEs) were recorded in 34.7%, with AE-related discontinuation in 3.4%. Conclusions: Esketamine induction was associated with marked improvement in depressive symptoms and suicidality, with acceptable tolerability under supervised administration. Longer-term registry follow-up and controlled comparative studies are needed to further define the benefit–risk profile beyond induction phase.
- 23 June 2026
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 69 (1) , 1-27
Open AccessReal-world effectiveness and safety of intranasal esketamine for treatment-resistant depression: data from the enTRD registry
Background: Real-world data for intranasal esketamine in treatment-resistant depression (TRD) are needed to characterize effectiveness, suicidality, and tolerability in routine care. We evaluated induction phase outcomes in outpatients with TRD treated at the University Hospital Vienna. Methods: This retrospective single-center registry study included adults with TRD initiating supervised intranasal esketamine. The primary endpoint was the change in clinician-rated depressive symptom severity (MADRS) from the pre-treatment (PV) to the end of induction (EOI) visit. MADRS scores across baseline (BL), PV, and EOI were analyzed using a mixed model for repeated measures. Secondary outcomes included MADRS three-factor change, self-rated depression score trajectories (PHQ-9), response/remission rates, suicidal ideation, and tolerability. Results: Of 229 screened patients, 176 initiated esketamine and 156 completed induction. MADRS at BL was 31.5 (SD 6.4), PHQ-9 was 18.5 (SD 4.7). In the primary model, adjusted mean MADRS was 30.3 at PV and 17.7 at EOI, yielding a change of −12.5 points (95%CI −14.1 to −11.0; p < 0.001; Hedges’ g = 1.8). All MADRS factors improved, with the largest reduction in the affective–anhedonic domain. PHQ-9 decreased steadily across treatments. Remission was 27.2% and response 57.4% at EOI. Suicidal ideation decreased significantly; no suicide or serious self-harm occurred during induction. Adverse events (AEs) were recorded in 34.7%, with AE-related discontinuation in 3.4%. Conclusions: Esketamine induction was associated with marked improvement in depressive symptoms and suicidality, with acceptable tolerability under supervised administration. Longer-term registry follow-up and controlled comparative studies are needed to further define the benefit–risk profile beyond induction phase.
- Open Access
A randomized, double-blind assessment of the effects of vortioxetine on functional connectivity in mild cognitive impairment
Vortioxetine has been reported to alleviate cognitive deficits in patients with depression, accompanied by changes in functional connectivity (FC). An open-label study suggested potential benefits of vortioxetine in patients with mild cognitive impairment (MCI), a condition also characterized by both cognitive and FC alterations. However, controlled studies are required to rule out nonspecific treatment effects and to determine whether FC changes are generalizable to this population. To address this, we collected resting-state functional magnetic resonance imaging data from 47 patients with MCI at baseline, and after four and twelve weeks of randomized, double-blind treatment with either 10 mg or 20 mg vortioxetine, or placebo. Brain-wide FC changes were assessed using network-based R-statistics, an extension of the network-based statistics approach that allows mixed-effects modeling. Analyses were conducted with two different brain atlases to evaluate agreement across parcellations. No vortioxetine-specific FC changes were observed. Instead, we identified a widespread network of predominantly reduced FC at four and twelve weeks across all groups (ps ≤ 0.012), with no additional significant changes between twelve and four weeks. Results showed high consistency across parcellations (rs ≥ 0.96). These reductions in FC may reflect a reversal of preceding hyperconnectivity, potentially linked to compensatory network remodeling in MCI, as described in prior studies. While our findings do not support vortioxetine-specific FC effects in MCI, future research including healthy controls, pre-MCI assessments, and comparison groups with MCI and depression will be important to disentangle disease-related and treatment-related FC changes.
Open AccessA randomized, double-blind assessment of the effects of vortioxetine on functional connectivity in mild cognitive impairment
Vortioxetine has been reported to alleviate cognitive deficits in patients with depression, accompanied by changes in functional connectivity (FC). An open-label study suggested potential benefits of vortioxetine in patients with mild cognitive impairment (MCI), a condition also characterized by both cognitive and FC alterations. However, controlled studies are required to rule out nonspecific treatment effects and to determine whether FC changes are generalizable to this population. To address this, we collected resting-state functional magnetic resonance imaging data from 47 patients with MCI at baseline, and after four and twelve weeks of randomized, double-blind treatment with either 10 mg or 20 mg vortioxetine, or placebo. Brain-wide FC changes were assessed using network-based R-statistics, an extension of the network-based statistics approach that allows mixed-effects modeling. Analyses were conducted with two different brain atlases to evaluate agreement across parcellations. No vortioxetine-specific FC changes were observed. Instead, we identified a widespread network of predominantly reduced FC at four and twelve weeks across all groups (ps ≤ 0.012), with no additional significant changes between twelve and four weeks. Results showed high consistency across parcellations (rs ≥ 0.96). These reductions in FC may reflect a reversal of preceding hyperconnectivity, potentially linked to compensatory network remodeling in MCI, as described in prior studies. While our findings do not support vortioxetine-specific FC effects in MCI, future research including healthy controls, pre-MCI assessments, and comparison groups with MCI and depression will be important to disentangle disease-related and treatment-related FC changes.
- Open Access
Summer and SERT: Effect of daily sunshine hours on SLC6A4 promoter methylation in seasonal affective disorder
Meteorological factors affect the serotonergic system, potentially influencing SLC6A4 promoter methylation in seasonal affective disorder (SAD). However, studies on how sunlight impacts methylation and modulates SERT activity in this context remain limited. This study aims to investigate the effect of average daily sunshine duration on SLC6A4 promoter methylation in a cohort consisting of both patients with SAD as well as healthy controls (HC). Methylation data were collected from 28 patients with SAD and 40 healthy controls (HC). Average methylation from four SLC6A4 promoter CpG sites was assessed. Daily sunlight data for Vienna, Austria (mean of 28 days before blood sampling), were obtained from ©GeoSphere Austria. A general linear model (GLM) analyzed SLC6A4 promoter methylation as the dependent variable, with sunlight hours as the independent variable, and group (SAD, HC), age, sex, and 5-HTTLPR/rs25531 as covariates. Exploratory analyses examined sunlight hours and methylation effects on Beck Depression Inventory (BDI) scores. Sunlight had a significant effect on SLC6A4 promoter methylation (p = 0.03), with more sunlight hours resulting in lower methylation (r = −0.25). However, the interaction between sunlight and group was non-significant, suggesting a rather general effect across both groups. Sunlight also influenced BDI scores (p < 0.01), with fewer sunlight hours leading to higher BDI scores (r = −0.25), which aligns with previous research. SLC6A4 promoter methylation had no significant effect on BDI scores. Our findings suggest that sunlight impacts SLC6A4 promoter methylation, but this effect appears general, not specific to SAD pathophysiology.
Open AccessSummer and SERT: Effect of daily sunshine hours on SLC6A4 promoter methylation in seasonal affective disorder
Meteorological factors affect the serotonergic system, potentially influencing SLC6A4 promoter methylation in seasonal affective disorder (SAD). However, studies on how sunlight impacts methylation and modulates SERT activity in this context remain limited. This study aims to investigate the effect of average daily sunshine duration on SLC6A4 promoter methylation in a cohort consisting of both patients with SAD as well as healthy controls (HC). Methylation data were collected from 28 patients with SAD and 40 healthy controls (HC). Average methylation from four SLC6A4 promoter CpG sites was assessed. Daily sunlight data for Vienna, Austria (mean of 28 days before blood sampling), were obtained from ©GeoSphere Austria. A general linear model (GLM) analyzed SLC6A4 promoter methylation as the dependent variable, with sunlight hours as the independent variable, and group (SAD, HC), age, sex, and 5-HTTLPR/rs25531 as covariates. Exploratory analyses examined sunlight hours and methylation effects on Beck Depression Inventory (BDI) scores. Sunlight had a significant effect on SLC6A4 promoter methylation (p = 0.03), with more sunlight hours resulting in lower methylation (r = −0.25). However, the interaction between sunlight and group was non-significant, suggesting a rather general effect across both groups. Sunlight also influenced BDI scores (p < 0.01), with fewer sunlight hours leading to higher BDI scores (r = −0.25), which aligns with previous research. SLC6A4 promoter methylation had no significant effect on BDI scores. Our findings suggest that sunlight impacts SLC6A4 promoter methylation, but this effect appears general, not specific to SAD pathophysiology.
- 24 March 2023
- Published by Springer Nature in psychopraxis. neuropraxis
- p. 1-4
Systemische Inflammation in Zusammenhang mit Depression und die Rolle von Omega-3-Fettsäuren
- 24 March 2023
- Published by Springer Nature in psychopraxis. neuropraxis
- p. 1-4
Systemische Inflammation in Zusammenhang mit Depression und die Rolle von Omega-3-Fettsäuren
- Open Access
- 25 October 2022
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 65 (1) , 1-19
Prescriptions of psychopharmacologic drugs in Austria in 2019 and 2020 – Implications of the COVID-19 pandemic
Background Measures to reduce the spread of the SARS-CoV-2 virus have an impact on the mental health of the general population. Drug prescription rates can be used as a surrogate marker to estimate help seeking and health parameters of a population. The aim of this study was to compare psychopharmacologic drug prescriptions in Austria from the start of the pandemic in 2020 over time and with the previous year and to investigate the impact of the COVID-19 lockdowns in 2020. Methods Data from the three largest public health insurances in Austria, covering over 98% of the general population, were analyzed. A total of 1,365,294 patients with a prescription of a psychopharmacologic drug in the months March to December in 2019 and 2020 were selected. Results There was no significant change in prescribed defined daily doses (DDDs) during the lockdowns. However, there was a stockpiling effect before and at the beginning of lockdown 1. The number of new patients initiating psychopharmacologic treatment was significantly reduced during lockdown 1 but not during lockdown 2. Conclusions The first COVID-19 lockdown in 2020 functioned as a barrier for new psychiatric patients seeking help, whereas the patients with ongoing treatments did not have significant problems. These results have to be taken into account for future planning, but follow-up studies are needed, as our results could be indicative of a change in the effect of the protective measures on the utilization of the healthcare system over time.
- 25 October 2022
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 65 (1) , 1-19
Open AccessPrescriptions of psychopharmacologic drugs in Austria in 2019 and 2020 – Implications of the COVID-19 pandemic
Background Measures to reduce the spread of the SARS-CoV-2 virus have an impact on the mental health of the general population. Drug prescription rates can be used as a surrogate marker to estimate help seeking and health parameters of a population. The aim of this study was to compare psychopharmacologic drug prescriptions in Austria from the start of the pandemic in 2020 over time and with the previous year and to investigate the impact of the COVID-19 lockdowns in 2020. Methods Data from the three largest public health insurances in Austria, covering over 98% of the general population, were analyzed. A total of 1,365,294 patients with a prescription of a psychopharmacologic drug in the months March to December in 2019 and 2020 were selected. Results There was no significant change in prescribed defined daily doses (DDDs) during the lockdowns. However, there was a stockpiling effect before and at the beginning of lockdown 1. The number of new patients initiating psychopharmacologic treatment was significantly reduced during lockdown 1 but not during lockdown 2. Conclusions The first COVID-19 lockdown in 2020 functioned as a barrier for new psychiatric patients seeking help, whereas the patients with ongoing treatments did not have significant problems. These results have to be taken into account for future planning, but follow-up studies are needed, as our results could be indicative of a change in the effect of the protective measures on the utilization of the healthcare system over time.
- Open Access
Effect of MAOA DNA methylation on human in vivo protein expression measured by [ 11 C]harmine PET in healthy and depressed individuals
Epigenetic modifications, such as DNA methylation, are understood as an intermediary between environmental factors affecting disease risk and pathophysiologic changes to brain structure and function. Cerebral monoamine oxidase A (MAO-A) levels are altered in depression, as are DNA methylation levels within the MAOA gene, particularly in the promoter / exon I / intron I region. An effect of MAOA methylation on peripheral protein expression was shown, but the extent to which methylation affects brain MAO-A levels is not fully understood. Here, the influence of average and CpG site-specific MAOA promoter / exon I / intron I region DNA methylation on global MAO-A distribution volume (V T ), an index of MAO-A density, was assessed via [ 11 C]harmine positron emission tomography in 22 patients suffering from winter-type seasonal affective disorder and 30 healthy controls. No significant influence of MAOA DNA methylation on global MAO-A V T was found, despite correction for health status (patients vs. controls), sex, season (methylation analysis in spring / summer vs. fall / winter) and MAOA variable number of tandem repeat genotype (VNTR; high vs. low expression groups). However, in female subjects, season affected average DNA methylation, with higher levels in spring and summer (p uncorr = 0.03). We thus did not find evidence for an effect of MAOA DNA methylation on brain MAO-A V T . In contrast to a previous study that demonstrated an effect of the methylation of a MAOA promoter region located further 5’ on brain MAO-A, in the present study MAOA methylation appears to affect brain protein levels to a limited extent. The observed effect of season on methylation levels is in accordance with extensive evidence for seasonal effects within the serotonergic system. Clinicaltrials.gov Identifier: NCT02582398 EUDAMED Number: CIV-AT-13-01-009583
Open AccessEffect of MAOA DNA methylation on human in vivo protein expression measured by [ 11 C]harmine PET in healthy and depressed individuals
Epigenetic modifications, such as DNA methylation, are understood as an intermediary between environmental factors affecting disease risk and pathophysiologic changes to brain structure and function. Cerebral monoamine oxidase A (MAO-A) levels are altered in depression, as are DNA methylation levels within the MAOA gene, particularly in the promoter / exon I / intron I region. An effect of MAOA methylation on peripheral protein expression was shown, but the extent to which methylation affects brain MAO-A levels is not fully understood. Here, the influence of average and CpG site-specific MAOA promoter / exon I / intron I region DNA methylation on global MAO-A distribution volume (V T ), an index of MAO-A density, was assessed via [ 11 C]harmine positron emission tomography in 22 patients suffering from winter-type seasonal affective disorder and 30 healthy controls. No significant influence of MAOA DNA methylation on global MAO-A V T was found, despite correction for health status (patients vs. controls), sex, season (methylation analysis in spring / summer vs. fall / winter) and MAOA variable number of tandem repeat genotype (VNTR; high vs. low expression groups). However, in female subjects, season affected average DNA methylation, with higher levels in spring and summer (p uncorr = 0.03). We thus did not find evidence for an effect of MAOA DNA methylation on brain MAO-A V T . In contrast to a previous study that demonstrated an effect of the methylation of a MAOA promoter region located further 5’ on brain MAO-A, in the present study MAOA methylation appears to affect brain protein levels to a limited extent. The observed effect of season on methylation levels is in accordance with extensive evidence for seasonal effects within the serotonergic system. Clinicaltrials.gov Identifier: NCT02582398 EUDAMED Number: CIV-AT-13-01-009583
- 1 October 2019
- Published by S. Karger AG in Psychotherapy and Psychosomatics
- Vol. 89 (1) , 17-24
The Efficacy of Light Therapy in the Treatment of Seasonal Affective Disorder: A Meta-Analysis of Randomized Controlled Trials
Background: Bright light therapy (BLT) has been used as a treatment for seasonal affective disorder (SAD) for over 30 years. This meta-analysis was aimed to assess the efficacy of BLT in the treatment of SAD in adults. Method: We performed a systematic literature search including randomized, single- or double-blind clinical trials investigating BLT (≥1,000 lx, light box or light visor) against dim light (≤400 lx) or sham/low-density negative ion generators as placebo. Only first-period data were used from crossover trials. The primary outcome was the post-treatment depression score measured by validated scales, and the secondary outcome was the rate of response to treatment. Results: A total of 19 studies finally met our predefined inclusion criteria. BLT was superior over placebo with a standardized mean difference of –0.37 (95% CI: –0.63 to –0.12) for depression ratings (18 studies, 610 patients) and a risk ratio of 1.42 (95% CI: 1.08–1.85) for response to active treatment (16 studies, 559 patients). We found no evidence for a publication bias, but moderate heterogeneity of the studies and a moderate-to-high risk of bias. Conclusions: BLT can be regarded as an effective treatment for SAD, but the available evidence stems from methodologically heterogeneous studies with small-to-medium sample sizes, necessitating larger high-quality clinical trials.
- 1 October 2019
- Published by S. Karger AG in Psychotherapy and Psychosomatics
- Vol. 89 (1) , 17-24
The Efficacy of Light Therapy in the Treatment of Seasonal Affective Disorder: A Meta-Analysis of Randomized Controlled Trials
Background: Bright light therapy (BLT) has been used as a treatment for seasonal affective disorder (SAD) for over 30 years. This meta-analysis was aimed to assess the efficacy of BLT in the treatment of SAD in adults. Method: We performed a systematic literature search including randomized, single- or double-blind clinical trials investigating BLT (≥1,000 lx, light box or light visor) against dim light (≤400 lx) or sham/low-density negative ion generators as placebo. Only first-period data were used from crossover trials. The primary outcome was the post-treatment depression score measured by validated scales, and the secondary outcome was the rate of response to treatment. Results: A total of 19 studies finally met our predefined inclusion criteria. BLT was superior over placebo with a standardized mean difference of –0.37 (95% CI: –0.63 to –0.12) for depression ratings (18 studies, 610 patients) and a risk ratio of 1.42 (95% CI: 1.08–1.85) for response to active treatment (16 studies, 559 patients). We found no evidence for a publication bias, but moderate heterogeneity of the studies and a moderate-to-high risk of bias. Conclusions: BLT can be regarded as an effective treatment for SAD, but the available evidence stems from methodologically heterogeneous studies with small-to-medium sample sizes, necessitating larger high-quality clinical trials.
- Open Access
- 24 September 2019
- Published by Springer Nature in Annals of General Psychiatry
- Vol. 18 (1) , 1-6
Alcohol consumption in Austrian physicians
Background: Alcohol is one of the leading exogenous causes for adverse health consequences in Europe. The aim of the present study was to examine the pattern of alcohol consumption in Austrian physicians.Methods: A telephone survey was conducted in 400 office-based physicians in Austria. Our questionnaire included the four questions of the CAGE questionnaire and questions to assess alcohol consumption on the previous day.Results: 131 participants (32.8%) completed the interview. 3.8% of the subjects had a CAGE score of 2 or higher indicating a problem with alcohol, but this rate was not statistically different from numbers reported for the general population (4.1%). 46.6% of our subjects had drunken alcohol on the previous day. Compared to the general population, the rate of having drunk alcohol yesterday was higher in both gender of our sample, but the amount of alcohol drunk was significantly lower. Doctors in rural areas had drunken alcohol more frequently and in greater quantities on the previous day than those in urban areas. There was a positive correlation between age and the amount of drinking on the previous day, and between age and CAGE scores. Furthermore, subjects who had consumed alcohol yesterday obtained higher scores on the CAGE.Conclusions: Our findings indicate that the rate of Austrian physicians with problematic alcohol consumption is similar to the general population. Physicians in rural areas and older doctors might be of higher risk for alcohol abuse.
- 24 September 2019
- Published by Springer Nature in Annals of General Psychiatry
- Vol. 18 (1) , 1-6
Open AccessAlcohol consumption in Austrian physicians
Background: Alcohol is one of the leading exogenous causes for adverse health consequences in Europe. The aim of the present study was to examine the pattern of alcohol consumption in Austrian physicians.Methods: A telephone survey was conducted in 400 office-based physicians in Austria. Our questionnaire included the four questions of the CAGE questionnaire and questions to assess alcohol consumption on the previous day.Results: 131 participants (32.8%) completed the interview. 3.8% of the subjects had a CAGE score of 2 or higher indicating a problem with alcohol, but this rate was not statistically different from numbers reported for the general population (4.1%). 46.6% of our subjects had drunken alcohol on the previous day. Compared to the general population, the rate of having drunk alcohol yesterday was higher in both gender of our sample, but the amount of alcohol drunk was significantly lower. Doctors in rural areas had drunken alcohol more frequently and in greater quantities on the previous day than those in urban areas. There was a positive correlation between age and the amount of drinking on the previous day, and between age and CAGE scores. Furthermore, subjects who had consumed alcohol yesterday obtained higher scores on the CAGE.Conclusions: Our findings indicate that the rate of Austrian physicians with problematic alcohol consumption is similar to the general population. Physicians in rural areas and older doctors might be of higher risk for alcohol abuse.
- Open Access
- 1 August 2019
- Published by Elsevier in Comprehensive Psychiatry
- Vol. 93, 20-26
Changes over time of the diagnostic and therapeutic characteristics of patients of a psychiatric intensive care unit in Austria
- 1 August 2019
- Published by Elsevier in Comprehensive Psychiatry
- Vol. 93, 20-26
Open AccessChanges over time of the diagnostic and therapeutic characteristics of patients of a psychiatric intensive care unit in Austria
- 1 June 2019
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 29 (6) , 711-719
Modeling the acute pharmacological response to selective serotonin reuptake inhibitors in human brain using simultaneous PET/MR imaging
- 1 June 2019
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 29 (6) , 711-719
Modeling the acute pharmacological response to selective serotonin reuptake inhibitors in human brain using simultaneous PET/MR imaging